' FDA  Plans To Withdraw Soy Health Claim - IGMPI

IGMPI is conferred with ASSOCHAM Services Excellence Award 2017: Our Directors Mr Syed S. Abbas & Mrs Rafat Abedi, Chief Advisor Dr Mahesh Gupta, Advisor Mr Amitabh Srivastava are being honoured by the Chief Guest & Honorable Member of Parliament Dr. Udit Raj

(L-R) Seetaraju Gembali, Managing Director, GSR Pharma Research; Vinod Arora, Principal Advisor, IGMPI (Moderator); Dr Girish Jain, President, Research & Development, Alkem Laboratories and Pramod Pimplikar, Managing Director, Shalina Laboratories

Maneuver your growth through adequate food safety knowledge

Maneuver your growth through adequate food safety knowledge

Where food safety is a culture, Maneuver your growth through adequate food safety knowledge

Where food safety is a culture, Maneuver your growth through adequate food safety knowledge

 

FDA  Plans To Withdraw Soy Health Claim

FDA  Plans To Withdraw Soy Health Claim

The FDA approved a health claim for soy protein and the reduced risk of coronary heart disease in the Oct. 26, 1999, issue of the Federal Register. As per this health claim soy protein included in a diet low in saturated fat and cholesterol may reduce the risk of coronary heart disease by lowering blood cholesterol levels. FDA is planning to withdraw this regulation as FDA recognizes some inconsistency in the results of recent clinical trials and conflicting findings on the relationship between soy protein and heart disease. Regarding questions about eating soy products, FDA has recommended consumers to continue to follow advice from the 2015-2020 Dietary Guidelines, according to which  a healthy eating pattern can include soy beverages and a variety of protein foods, including soy products.

26a65a87fee5f557de982f854d477cba44444444444444444444444444444
Menu Title